Table of Content


Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Parkinson’s disease therapeutics industry 360 degree synopsis, 2016 - 2027 (USD Million)
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Route of administration trends
2.1.4 Patient trends
2.1.5 Regional trends
Chapter 3 Parkinson’s Disease Therapeutic Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 - 2027 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Growing aging population coupled with increasing prevalence of Parkinson’s disease
3.3.1.2 Increasing number of drug approvals
3.3.1.3 Growing awareness among the population
3.3.1.4 Growing funding in R&D
3.3.2 Industry pitfalls & challenges
3.3.2.1 High cost of the treatment
3.4 Growth potential analysis
3.4.1 By drug class
3.4.2 By route of administration
3.4.3 By patient
3.5 COVID-19 impact analysis
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 Competitive landscape, 2019
3.8.1 Competitive matrix analysis
3.9 PESTEL analysis
Chapter 4 Parkinson’s Disease Therapeutics Market, By Drug Class
4.1 Key segment trends
4.2 Levodopa/Carbidopa
4.2.1 Market size, by region, 2016 - 2027 (USD Million)
4.3 Dopamine Agonist
4.3.1 Market size, by region, 2016 - 2027 (USD Million)
4.4 Adenosine A2A Antagonist
4.4.1 Market size, by region, 2016 - 2027 (USD Million)
4.5 COMT Inhibitors
4.5.1 Market size, by region, 2016 - 2027 (USD Million)
4.6 MAO-B Inhibitors
4.6.1 Market size, by region, 2016 - 2027 (USD Million)
4.7 Glutamate Antagonist
4.7.1 Market size, by region, 2016 - 2027 (USD Million)
4.8 Others
4.8.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 5 Parkinson’s Disease Therapeutics Market, By Route of Administration
5.1 Key segment trends
5.2 Oral
5.2.1 Market size, by region, 2016 - 2027 (USD Million)
5.3 Subcutaneous
5.3.1 Market size, by region, 2016 - 2027 (USD Million)
5.4 Transdermal
5.4.1 Market size, by region, 2016 - 2027 (USD Million)
5.5 Others
5.5.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 Parkinson’s Disease Therapeutics Market, By Patient
6.1 Key segment trends
6.2 Adult
6.2.1 Market size, by region, 2016 - 2027 (USD Million)
6.3 Pediatric
6.3.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 7 Parkinson’s Disease Therapeutics Market, By Region
7.1 Key segment trends
7.2 North America
7.2.1 Market size, by country, 2016 - 2027 (USD Million)
7.2.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.4 Market size, by patient, 2016 - 2027 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.2.6 Canada
7.2.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.2.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.2.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3 Europe
7.3.1 Market size, by country, 2016 - 2027 (USD Million)
7.3.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.4 Market size, by patient, 2016 - 2027 (USD Million)
7.3.5 Germany
7.3.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.6 UK
7.3.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.7 France
7.3.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.8 Spain
7.3.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.8.3 Market size, by patient, 2016 - 2027 (USD Million)
7.3.9 Italy
7.3.9.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.3.9.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.3.9.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Market size, by country, 2016 - 2027 (USD Million)
7.4.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.4 Market size, by patient, 2016 - 2027 (USD Million)
7.4.5 Japan
7.4.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.6 China
7.4.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.7 India
7.4.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.8 Australia
7.4.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.8.3 Market size, by patient, 2016 - 2027 (USD Million)
7.4.9 South Korea
7.4.9.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.4.9.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.4.9.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5 Latin America
7.5.1 Market size, by country, 2016 - 2027 (USD Million)
7.5.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.4 Market size, by patient, 2016 - 2027 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.6.3 Market size, by patient, 2016 - 2027 (USD Million)
7.5.7 Argentina
7.5.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.5.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.5.7.3 Market size, by patient, 2016 - 2027 (USD Million)
7.6 Middle East and Africa
7.6.1 Market size, by country, 2016 - 2027 (USD Million)
7.6.2 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.3 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.4 Market size, by patient, 2016 - 2027 (USD Million)
7.6.5 South Africa
7.6.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.5.3 Market size, by patient, 2016 - 2027 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
7.6.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
7.6.6.3 Market size, by patient, 2016 - 2027 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2019
8.2 Kyowa Kirin Inc
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Product landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 Acadia Pharmaceuticals
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Product landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 Acorda Therapeutics Inc
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Product landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 Roche
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Product landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Sumitoma Dainippon pharma co ltd
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Product landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 Orion Corporation
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Product landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 H Lundbeck
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Product landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Amneal Pharmaceuticals
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Product landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 AbbVie Inc.
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Product landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 Boehringer Ingelheim
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Product landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 UCB
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Product landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Adamas Pharmaceutical Inc.
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Product landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
8.14 Teva Pharmaceutical Industries Ltd.
8.14.1 Business overview
8.14.2 Financial data
8.14.3 Product landscape
8.14.4 Strategic outlook
8.14.5 SWOT analysis
8.15 Desitin Arzneimittel GmbH
8.15.1 Business overview
8.15.2 Financial data
8.15.3 Product landscape
8.15.4 Strategic outlook
8.15.5 SWOT analysis
8.16 Supernus Pharmaceuticals
8.16.1 Business overview
8.16.2 Financial data
8.16.3 Product landscape
8.16.4 Strategic outlook
8.16.5 SWOT analysis



List of Tables

Data Tables
TABLE 1. Parkinson’s disease therapeutics industry 360 degree synopsis, 2016-2027
TABLE 2. Global Parkinson’s disease therapeutics market, 2016 - 2020 (USD Million)
TABLE 3. Global Parkinson’s disease therapeutics market, 2021 - 2027 (USD Million)
TABLE 4. Global Parkinson’s disease therapeutics market, by drug class, 2016 - 2020 (USD Million)
TABLE 5. Global Parkinson’s disease therapeutics market, by drug class, 2021 - 2027 (USD Million)
TABLE 6. Global Parkinson’s disease therapeutics market, by route of administration, 2016 - 2020 (USD Million)
TABLE 7. Global Parkinson’s disease therapeutics market, by route of administration, 2021 - 2027 (USD Million)
TABLE 8. Global Parkinson’s disease therapeutics market, by patient, 2016 - 2020 (USD Million)
TABLE 9. Global Parkinson’s disease therapeutics market, by patient, 2021 - 2027 (USD Million)
TABLE 10. Global Parkinson’s disease therapeutics market, by region, 2016 - 2020 (USD Million)
TABLE 11. Global Parkinson’s disease therapeutics market, by region, 2021 - 2027 (USD Million)
TABLE 12. Industry impact forces
TABLE 13. Levodopa/Carbidopa market size, by region, 2016 - 2020 (USD Million)
TABLE 14. Levodopa/Carbidopa market size, by region, 2021 - 2027 (USD Million)
TABLE 15. Dopamine agonist market size, by region, 2016 - 2020 (USD Million)
TABLE 16. Dopamine agonist market size, by region, 2021 - 2027 (USD Million)
TABLE 17. Adenosine A2A antagonist market size, by region, 2016 - 2020 (USD Million)
TABLE 18. Adenosine A2A antagonist market size, by region, 2021 - 2027 (USD Million)
TABLE 19. COMT inhibitors market size, by region, 2016 - 2020 (USD Million)
TABLE 20. COMT inhibitors market size, by region, 2021 - 2027 (USD Million)
TABLE 21. MAO-B inhibitors market size, by region, 2016 - 2020 (USD Million)
TABLE 22. MAO-B inhibitors market size, by region, 2021 - 2027 (USD Million)
TABLE 23. Glutamate antagonist market size, by region, 2016 - 2020 (USD Million)
TABLE 24. Glutamate antagonist market size, by region, 2021 - 2027 (USD Million)
TABLE 25. Others market size, by region, 2016 - 2020 (USD Million)
TABLE 26. Others market size, by region, 2021 - 2027 (USD Million)
TABLE 27. Oral market size, by region, 2016 - 2020 (USD Million)
TABLE 28. Oral market size, by region, 2021 - 2027 (USD Million)
TABLE 29. Subcutaneous market size, by region, 2016 - 2020 (USD Million)
TABLE 30. Subcutaneous market size, by region, 2021 - 2027 (USD Million)
TABLE 31. Transdermal market size, by region, 2016 - 2020 (USD Million)
TABLE 32. Transdermal market size, by region, 2021 - 2027 (USD Million)
TABLE 33. Others market size, by region, 2016 - 2020 (USD Million)
TABLE 34. Others market size, by region, 2021 - 2027 (USD Million)
TABLE 35. Adult market size, by region, 2016 - 2020 (USD Million)
TABLE 36. Adult market size, by region, 2021 - 2027 (USD Million)
TABLE 37. Pediatric market size, by region, 2016 - 2020 (USD Million)
TABLE 38. Pediatric market size, by region, 2021 - 2027 (USD Million)
TABLE 39. North America Parkinson’s disease therapeutics market size, by country, 2016 - 2020 (USD Million)
TABLE 40. North America Parkinson’s disease therapeutics market size, by country, 2021 - 2027 (USD Million)
TABLE 41. North America Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 42. North America Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 43. North America Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 44. North America Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 45. North America Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 46. North America Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 47. U.S. Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 48. U.S. Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 49. U.S. Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 50. U.S. Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 51. U.S. Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 52. U.S. Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 53. Canada Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 54. Canada Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 55. Canada Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 56. Canada Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 57. Canada Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 58. Canada Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 59. Europe Parkinson’s disease therapeutics market size, by country, 2016 - 2020 (USD Million)
TABLE 60. Europe Parkinson’s disease therapeutics market size, by country, 2021 - 2027 (USD Million)
TABLE 61. Europe Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 62. Europe Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 63. Europe Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 64. Europe Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 65. Europe Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 66. Europe Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 67. Germany Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 68. Germany Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 69. Germany Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 70. Germany Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 71. Germany Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 72. Germany Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 73. UK Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 74. UK Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 75. UK Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 76. UK Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 77. UK Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 78. UK Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 79. France Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 80. France Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 81. France Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 82. France Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 83. France Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 84. France Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 85. Spain Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 86. Spain Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 87. Spain Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 88. Spain Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 89. Spain Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 90. Spain Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 91. Italy Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 92. Italy Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 93. Italy Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 94. Italy Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 95. Italy Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 96. Italy Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 97. Asia Pacific Parkinson’s disease therapeutics market size, by country, 2016 - 2020 (USD Million)
TABLE 98. Asia Pacific Parkinson’s disease therapeutics market size, by country, 2021 - 2027 (USD Million)
TABLE 99. Asia Pacific Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 100. Asia Pacific Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 101. Asia Pacific Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 102. Asia Pacific Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 103. Asia Pacific Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 104. Asia Pacific Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 105. Japan Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 106. Japan Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 107. Japan Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 108. Japan Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 109. Japan Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 110. Japan Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 111. China Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 112. China Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 113. China Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 114. China Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 115. China Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 116. China Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 117. India Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 118. India Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 119. India Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 120. India Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 121. India Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 122. India Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 123. South Korea Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 124. South Korea Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 125. South Korea Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 126. South Korea Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 127. South Korea Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 128. South Korea Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 129. Australia Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 130. Australia Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 131. Australia Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 132. Australia Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 133. Australia Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 134. Australia Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 135. Latin America Parkinson’s disease therapeutics market size, by country, 2016 - 2020 (USD Million)
TABLE 136. Latin America Parkinson’s disease therapeutics market size, by country, 2021 - 2027 (USD Million)
TABLE 137. Latin America Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 138. Latin America Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 139. Latin America Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 140. Latin America Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 141. Latin America Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 142. Latin America Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 143. Brazil Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 144. Brazil Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 145. Brazil Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 146. Brazil Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 147. Brazil Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 148. Brazil Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 149. Mexico Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 150. Mexico Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 151. Mexico Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 152. Mexico Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 153. Mexico Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 154. Mexico Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 155. Argentina Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 156. Argentina Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 157. Argentina Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 158. Argentina Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 159. Argentina Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 160. Argentina Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 161. MEA Parkinson’s disease therapeutics market size, by country, 2016 - 2020 (USD Million)
TABLE 162. MEA Parkinson’s disease therapeutics market size, by country, 2021 - 2027 (USD Million)
TABLE 163. MEA Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 164. MEA Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 165. MEA Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 166. MEA Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 167. MEA Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 168. MEA Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 169. South Africa Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 170. South Africa Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 171. South Africa Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 172. South Africa Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 173. South Africa Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 174. South Africa Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)
TABLE 175. Saudi Arabia Parkinson’s disease therapeutics market size, by drug class, 2016 - 2020 (USD Million)
TABLE 176. Saudi Arabia Parkinson’s disease therapeutics market size, by drug class, 2021 - 2027 (USD Million)
TABLE 177. Saudi Arabia Parkinson’s disease therapeutics market size, by route of administration, 2016 - 2020 (USD Million)
TABLE 178. Saudi Arabia Parkinson’s disease therapeutics market size, by route of administration, 2021 - 2027 (USD Million)
TABLE 179. Saudi Arabia Parkinson’s disease therapeutics market size, by patient, 2016 - 2020 (USD Million)
TABLE 180. Saudi Arabia Parkinson’s disease therapeutics market size, by patient, 2021 - 2027 (USD Million)

Charts & Figures
FIG. 1 Top-down approach
FIG. 2 Data validation
FIG. 3 Parkinson’s disease therapeutics industry 360 degree synopsis, 2016 - 2027
FIG. 4 Industry segmentation
FIG. 5 Global Parkinson’s disease therapeutics market, 2016 - 2027 (USD Million)
FIG. 6 Growth potential analysis, by drug class
FIG. 7 Growth potential analysis, by route of administration
FIG. 8 Growth potential analysis, by patient
FIG. 9 Porter’s analysis
FIG. 10 Competitive matrix analysis
FIG. 11 PESTEL analysis
FIG. 12 Key segment trends, by drug class
FIG. 13 Key segment trends, by route of administration
FIG. 14 Key segment trends, by patient
FIG. 15 Competitive dashboard, 2019